2. Search Result
Search Result
Results for "

Lactate Dehydrogenase Inhibitor

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2498
    Glomeratose A

    		Lactate Dehydrogenase Others
    Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia .
    Glomeratose A
  • HY-100742B
    (S)-GNE-140

    		Lactate Dehydrogenase Cancer
    (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
    (S)-GNE-140
  • HY-100681
    GSK2837808A
    35+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A
  • HY-111108
    LDH-IN-1
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
    LDH-IN-1
  • HY-110119
    Galloflavin potassium

    		Lactate Dehydrogenase Apoptosis Others
    Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis .
    Galloflavin potassium
  • HY-151243
    NCATS-SM1441

    		Lactate Dehydrogenase Cancer
    NCATS-SM1441 (compound 52) is a lactate dehydrogenase (LDH) inhibitor (IC50=40 nM). By inhibiting the activity of LDH, NCATS-SM1441 is able to reduce the production of lactic acid in cancer cells, helping to slow or stop the proliferation of cancer cells. NCATS-SM1441 can be used to study cancer metabolism .
    NCATS-SM1441
  • HY-P2807J
    L-Lactate Dehydrogenase (L-LDH), pig muscle

    		Lactate Dehydrogenase Metabolic Disease
    L-Lactate Dehydrogenase (L-LDH), pig muscle is an L-lactate dehydrogenase found in pig muscle, mainly present in anaerobic tissues (skeletal muscle, red blood cells). L-Lactate Dehydrogenase (L-LDH), pig muscle can interact with acidic liposomes at low pH, causing protein to adsorb onto the liposomes and inhibit enzyme activity. The IC50 values for L-Lactate Dehydrogenase (L-LDH), pig muscle are 0.05 μM for cardiolipin and 1.3 μM for phosphatidylserine liposomes .
    L-Lactate Dehydrogenase (L-LDH), pig muscle
  • HY-154865
    Anticancer agent 121

    		Lactate Dehydrogenase Cancer
    Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 121
  • HY-154866
    Anticancer agent 122

    		Lactate Dehydrogenase Cancer
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
    Anticancer agent 122
  • HY-162627
    LDHA-IN-6

    		Lactate Dehydrogenase Cancer
    LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity .
    LDHA-IN-6
  • HY-18968
    AZ-33
    1 Publications Verification

    LDHA-IN-4

    		 Lactate Dehydrogenase Cancer
    AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM .
    AZ-33
  • HY-162629
    LDHA-IN-7

    		Lactate Dehydrogenase Cancer
    LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC50s of 72 nM and 1.2 Μm, respectively .
    LDHA-IN-7
  • HY-W013032
    Oxamic acid
    Maximum Cited Publications
    41 Publications Verification

    Oxamidic acid

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid
  • HY-100742
    GNE-140 racemate
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .
    GNE-140 racemate
  • HY-W013032A
    Oxamic acid sodium
    Maximum Cited Publications
    41 Publications Verification

    Sodium oxamate

    		 Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .
    Oxamic acid sodium
  • HY-150753
    RS6212

    		Oxidative Phosphorylation Lactate Dehydrogenase Cancer
    RS6212 is a specific LDH (lactate dehydrogenase) inhibitor with an IC50 value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines .
    RS6212
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-139319
    LDHA-IN-3
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
    LDHA-IN-3
  • HY-131485A
    3-Acetylpyridine adenine dinucleotide, 95%

    3-APAD, 95%; 3-Acetylpyridine NAD, 95%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 95% (3-APAD, 95%)is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 95% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 95%
  • HY-100742A
    (R)-GNE-140
    15+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
    (R)-GNE-140
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-W040118
    Galloflavin
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .
    Galloflavin
  • HY-169060
    LDHA-IN-8

    		Lactate Dehydrogenase Cancer
    LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC50 value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .
    LDHA-IN-8
  • HY-147216A
    AXKO-0046 dihydrochloride
    5 Publications Verification

    		 Lactate Dehydrogenase Metabolic Disease Inflammation/Immunology Cancer
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism .
    AXKO-0046 dihydrochloride
  • HY-178461
    LDHA-IN-10

    		Lactate Dehydrogenase Cancer
    LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .
    LDHA-IN-10
  • HY-147216
    AXKO-0046
    5 Publications Verification

    		 Lactate Dehydrogenase Cancer
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism .
    AXKO-0046
  • HY-N2177
    3-Dehydrotrametenolic acid

    		Lactate Dehydrogenase Apoptosis Cancer
    3-​Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-​Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-​Dehydrotrametenolic acid induces apoptosis and has anticancer activity .
    3-Dehydrotrametenolic acid
  • HY-W013032R
    Oxamic acid (Standard)

    Oxamidic acid (Standard)

    		 Reference Standards Lactate Dehydrogenase Apoptosis Cancer
    Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].
    Oxamic acid (Standard)
  • HY-Y0445A
    Sodium dichloroacetate
    20+ Cited Publications

    		 PDK-1 NKCC PDHK Reactive Oxygen Species (ROS) Apoptosis Cancer
    Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na +-K +-2Cl − cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers .
    Sodium dichloroacetate
  • HY-16214
    FX-11
    25+ Cited Publications

    LDHA Inhibitor FX11

    		 Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) Cancer
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
    FX-11
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-153129
    EP2 receptor antagonist-2

    		Prostaglandin Receptor Endocrinology
    EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .
    EP2 receptor antagonist-2
  • HY-152670
    JC2-11
    1 Publications Verification

    		 NOD-like Receptor (NLR) AIM2 Inflammation/Immunology
    JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .
    JC2-11
  • HY-176836
    PNR-3-82

    		Endonuclease Cancer
    PNR-3-82 is a selective Apoptotic endonuclease G (EndoG) inhibitor with an IC50 of 0.61  μM for EndoG over DNase I. PNR-3-82 does not inhibit five cell death-related enzymes including DNase II, RNase A, proteinase, lactate dehydrogenase and superoxide dismutase 1. PNR-3-82 has a cytoprotective activity and blocks Cisplatin (HY-17394) and Docetaxel (HY-B0011)-induced cell death. PNR-3-82 can be used for cell injuries research .
    PNR-3-82
  • HY-168096
    iNOs-IN-5

    		NO Synthase Apoptosis Cardiovascular Disease Neurological Disease
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable .
    iNOs-IN-5
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Apoptosis Cancer
    NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
    NHI-2
  • HY-176835
    PNR-3-80

    		Endonuclease Cancer
    PNR-3-80 is a selective Apoptotic endonuclease G (EndoG) inhibitor with an IC50 of 0.67  μM for EndoG over DNase I. PNR-3-80 does not have inhibitory activities for DNase II, RNase A, proteinase, lactate dehydrogenase and superoxide dismutase 1. PNR-3-80 has a potent cytoprotective activity, and it significantly protects human prostate carcinoma cells from Cisplatin (HY-17394) and Docetaxel (HY-B0011)-induced cell death and represses Etoposide (HY-13629)-induced DNA damage and autophagy. PNR-3-80 can be used for cell injuries research .
    PNR-3-80

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: